Emmaus Life Sciences Inc
OTC:EMMA
Emmaus Life Sciences Inc
Research & Development
Emmaus Life Sciences Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Emmaus Life Sciences Inc
OTC:EMMA
|
Research & Development
-$419k
|
CAGR 3-Years
43%
|
CAGR 5-Years
31%
|
CAGR 10-Years
6%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Emmaus Life Sciences Inc
Glance View
Emmaus Life Sciences, Inc. operates as a biopharmaceutical company. The company is headquartered in Torrance, California and currently employs 58 full-time employees. The company went IPO on 2000-05-09. The Company’s lead product, Endari was approved by the United States Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission. Endari’s safety profile was like the placebo and Endari was well-tolerated in pediatric and adult patients alike. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003 and ELS002. The Company’s subsidiaries include EMI Holding, Inc., Emmaus Medical, Inc., Emmaus Medical Japan, Inc., Newfield Nutrition Corporation, Emmaus Medical Europe Limited, Emmaus Medical Europe Limited and Emmaus Life Sciences, Co. Ltd.
See Also
What is Emmaus Life Sciences Inc's Research & Development?
Research & Development
-419k
USD
Based on the financial report for Sep 30, 2025, Emmaus Life Sciences Inc's Research & Development amounts to -419k USD.
What is Emmaus Life Sciences Inc's Research & Development growth rate?
Research & Development CAGR 10Y
6%
Over the last year, the Research & Development growth was 39%. The average annual Research & Development growth rates for Emmaus Life Sciences Inc have been 43% over the past three years , 31% over the past five years , and 6% over the past ten years .
